Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Malignant Glioma
Interventions
DRUG

Palonosetron (PALO)

Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.

Trial Locations (1)

27710

The Preston Robert Tisch Brain Tumor Center at Duke, Durham

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

Duke University

OTHER